FGD4 (Frabin) Overexpression in Pancreatic Neuroendocrine Neoplasms.
Journal
Pancreas
ISSN: 1536-4828
Titre abrégé: Pancreas
Pays: United States
ID NLM: 8608542
Informations de publication
Date de publication:
Historique:
entrez:
6
11
2019
pubmed:
7
11
2019
medline:
22
9
2020
Statut:
ppublish
Résumé
The pathogenesis of pancreatic neuroendocrine tumors (PNETs) is still unclear. We propose Frabin as a new molecular alteration in PNETs. Frabin is a guanine nucleotide exchange factor playing a role in mediating actin cytoskeleton changes during cell migration, morphogenesis, polarization, and division. Patients with PNETs of different grades were assessed for Frabin expression using immunohistochemistry and tissue microarray. The tissue microarray included 12 grade 1 and 3 grade 2 PNETs and 14 grade 3 pancreatic neuroendocrine carcinomas (PECAs). Frabin immunostain was scored with Allred system. Statistical analysis used SAS and R software. Immunohistochemistry scores were correlated with tumor grade and stage. The Spearman correlation coefficient was calculated with P values. Pancreatic neuroendocrine tumors were graded according to the World Health Organization 2017 guidelines. Frabin was expressed by 24 (82.7%) of the PNET/PECA studied. Only 5 (17.2%) of the 29 PNETs/PECA evaluated were Frabin negative. Frabin expression was cytoplasmic in all cases. We found a significant positive correlation (ρ = 0.47) between Frabin immunohistochemistry score and tumor grade (P = 0.01). No correlation was found between Frabin expression and tumor stage (P = 0.91). We report Frabin overexpression as a novel molecular alteration occurring in PNETs/PECAs.
Identifiants
pubmed: 31688594
doi: 10.1097/MPA.0000000000001422
pii: 00006676-201911000-00013
pmc: PMC7771383
mid: NIHMS1653155
doi:
Substances chimiques
FGD4 protein, human
0
Microfilament Proteins
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1307-1311Subventions
Organisme : NCI NIH HHS
ID : P30 CA076292
Pays : United States
Références
J Biol Chem. 1999 Sep 3;274(36):25197-200
pubmed: 10464238
Cancer Treat Rev. 2014 Apr;40(3):376-89
pubmed: 24296109
Mol Cancer. 2014 Jan 03;13:1
pubmed: 24387052
PLoS One. 2014 Oct 30;9(10):e111534
pubmed: 25356636
J Gastrointest Oncol. 2012 Sep;3(3):182-8
pubmed: 22943010
Pancreas. 2017 Nov/Dec;46(10):1354-1358
pubmed: 28984786
J Biol Chem. 1998 Jul 24;273(30):18697-700
pubmed: 9668039
Am J Hum Genet. 2007 Jul;81(1):1-16
pubmed: 17564959
Sci Rep. 2018 May 8;8(1):7271
pubmed: 29739948
BMC Cancer. 2018 Dec 17;18(1):1257
pubmed: 30558664
Arch Pathol Lab Med. 2016 May;140(5):437-48
pubmed: 27128301
Nat Rev Cancer. 2011 Jul 22;11(8):573-87
pubmed: 21779009
BMC Surg. 2015 Apr 25;15:49
pubmed: 25928025
Oncogene. 2000 Jun 22;19(27):3050-8
pubmed: 10871857
J Clin Oncol. 2011 Mar 1;29(7):934-43
pubmed: 21263089
Gland Surg. 2014 Nov;3(4):258-75
pubmed: 25493258
Cancer. 2009 Feb 15;115(4):741-51
pubmed: 19130464
Genes Cells. 2003 Dec;8(12):1019-27
pubmed: 14750956
Mod Pathol. 1998 Feb;11(2):155-68
pubmed: 9504686